blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2820048

EP2820048 - ANTIBODIES TO MATRIX METALLOPROTEINASE 9 [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  21.02.2020
Database last updated on 31.08.2024
FormerThe patent has been granted
Status updated on  15.03.2019
FormerGrant of patent is intended
Status updated on  16.10.2018
FormerExamination is in progress
Status updated on  30.07.2018
FormerGrant of patent is intended
Status updated on  17.05.2018
FormerExamination is in progress
Status updated on  18.11.2016
Most recent event   Tooltip08.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 10.08.2022  [2022/32]
Applicant(s)For all designated states
Gilead Biologics, Inc.
333 Lakeside Drive
Foster City, CA 94404 / US
[2015/02]
Inventor(s)01 / SMITH, Victoria
333 Lakeside Drive
Foster City, CA 94404 / US
02 / MCCAULEY, Scott
660 Teresita Boulevard
San Francisco, CA 94127 / US
 [2015/02]
Representative(s)Schnappauf, Georg, et al
ZSP Patentanwälte PartG mbB
Hansastraße 32
80686 München / DE
[2019/16]
Former [2015/02]Carpmaels & Ransford LLP
One Southampton Row
London WC1B 5HA / GB
Application number, filing date12708473.929.02.2012
[2019/16]
WO2012US27160
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2013130078
Date:06.09.2013
Language:EN
[2013/36]
Type: A1 Application with search report 
No.:EP2820048
Date:07.01.2015
Language:EN
The application published by WIPO in one of the EPO official languages on 06.09.2013 takes the place of the publication of the European patent application.
[2015/02]
Type: B1 Patent specification 
No.:EP2820048
Date:17.04.2019
Language:EN
[2019/16]
Search report(s)International search report - published on:EP06.09.2013
ClassificationIPC:C07K16/40, C12N9/64, G01N33/573, A61K39/00
[2017/39]
CPC:
C07K16/40 (EP,US); A61P43/00 (EP); C12N9/6491 (EP,US);
C12Y304/24035 (EP,US); G01N33/573 (EP,US); A61K2039/505 (EP,US);
A61K2039/54 (EP,US); A61K2039/545 (EP,US); C07K2317/24 (US);
C07K2317/34 (EP,US); C07K2317/56 (EP,US); C07K2317/565 (EP,US);
C07K2317/76 (EP,US); C07K2317/92 (EP,US); G01N2333/96494 (EP,US) (-)
Former IPC [2015/02]C07K16/40, C12N9/64, A61K39/395
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2015/02]
Extension statesBA26.09.2014
ME26.09.2014
TitleGerman:ANTIKÖRPER GEGEN MATRIX-METALLOPROTEINASE-9[2015/02]
English:ANTIBODIES TO MATRIX METALLOPROTEINASE 9[2015/02]
French:ANTICORPS DIRIGÉS CONTRE LA MÉTALLOPROTÉINASE 9 DE LA MATRICE[2015/02]
Entry into regional phase26.09.2014National basic fee paid 
26.09.2014Designation fee(s) paid 
26.09.2014Examination fee paid 
Examination procedure08.02.2013Request for preliminary examination filed
International Preliminary Examining Authority: US
26.09.2014Examination requested  [2015/02]
08.05.2015Amendment by applicant (claims and/or description)
18.01.2016Despatch of a communication from the examining division (Time limit: M04)
27.05.2016Reply to a communication from the examining division
12.07.2016Despatch of a communication from the examining division (Time limit: M06)
23.01.2017Reply to a communication from the examining division
02.02.2017Despatch of a communication from the examining division (Time limit: M06)
17.07.2017Reply to a communication from the examining division
25.09.2017Despatch of a communication from the examining division (Time limit: M06)
21.03.2018Reply to a communication from the examining division
18.05.2018Communication of intention to grant the patent
30.07.2018Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
02.08.2018Despatch of a communication from the examining division (Time limit: M02)
12.09.2018Reply to a communication from the examining division
17.10.2018Communication of intention to grant the patent
13.02.2019Fee for grant paid
13.02.2019Fee for publishing/printing paid
13.02.2019Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  18.01.2016
Opposition(s)20.01.2020No opposition filed within time limit [2020/13]
Fees paidRenewal fee
02.09.2014Renewal fee patent year 03
26.02.2015Renewal fee patent year 04
26.02.2016Renewal fee patent year 05
27.02.2017Renewal fee patent year 06
27.02.2018Renewal fee patent year 07
27.02.2019Renewal fee patent year 08
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU29.02.2012
AL17.04.2019
AT17.04.2019
CY17.04.2019
CZ17.04.2019
DK17.04.2019
EE17.04.2019
FI17.04.2019
HR17.04.2019
LT17.04.2019
LV17.04.2019
MC17.04.2019
MK17.04.2019
MT17.04.2019
NL17.04.2019
PL17.04.2019
RO17.04.2019
RS17.04.2019
SE17.04.2019
SI17.04.2019
SK17.04.2019
SM17.04.2019
TR17.04.2019
BG17.07.2019
NO17.07.2019
GR18.07.2019
IS17.08.2019
PT17.08.2019
[2022/32]
Former [2022/27]HU29.02.2012
AL17.04.2019
AT17.04.2019
CY17.04.2019
CZ17.04.2019
DK17.04.2019
EE17.04.2019
FI17.04.2019
HR17.04.2019
LT17.04.2019
LV17.04.2019
MC17.04.2019
MT17.04.2019
NL17.04.2019
PL17.04.2019
RO17.04.2019
RS17.04.2019
SE17.04.2019
SI17.04.2019
SK17.04.2019
SM17.04.2019
TR17.04.2019
BG17.07.2019
NO17.07.2019
GR18.07.2019
IS17.08.2019
PT17.08.2019
Former [2020/49]AL17.04.2019
AT17.04.2019
CZ17.04.2019
DK17.04.2019
EE17.04.2019
FI17.04.2019
HR17.04.2019
LT17.04.2019
LV17.04.2019
MC17.04.2019
NL17.04.2019
PL17.04.2019
RO17.04.2019
RS17.04.2019
SE17.04.2019
SI17.04.2019
SK17.04.2019
SM17.04.2019
TR17.04.2019
BG17.07.2019
NO17.07.2019
GR18.07.2019
IS17.08.2019
PT17.08.2019
Former [2020/26]AL17.04.2019
AT17.04.2019
CZ17.04.2019
DK17.04.2019
EE17.04.2019
FI17.04.2019
HR17.04.2019
LT17.04.2019
LV17.04.2019
NL17.04.2019
PL17.04.2019
RO17.04.2019
RS17.04.2019
SE17.04.2019
SI17.04.2019
SK17.04.2019
SM17.04.2019
TR17.04.2019
BG17.07.2019
NO17.07.2019
GR18.07.2019
IS17.08.2019
PT17.08.2019
Former [2020/17]AL17.04.2019
AT17.04.2019
CZ17.04.2019
DK17.04.2019
EE17.04.2019
FI17.04.2019
HR17.04.2019
LT17.04.2019
LV17.04.2019
NL17.04.2019
PL17.04.2019
RO17.04.2019
RS17.04.2019
SE17.04.2019
SK17.04.2019
SM17.04.2019
TR17.04.2019
BG17.07.2019
NO17.07.2019
GR18.07.2019
IS17.08.2019
PT17.08.2019
Former [2020/14]AL17.04.2019
AT17.04.2019
CZ17.04.2019
DK17.04.2019
EE17.04.2019
FI17.04.2019
HR17.04.2019
LT17.04.2019
LV17.04.2019
NL17.04.2019
PL17.04.2019
RO17.04.2019
RS17.04.2019
SE17.04.2019
SK17.04.2019
SM17.04.2019
BG17.07.2019
NO17.07.2019
GR18.07.2019
IS17.08.2019
PT17.08.2019
Former [2020/11]AL17.04.2019
AT17.04.2019
CZ17.04.2019
DK17.04.2019
EE17.04.2019
FI17.04.2019
HR17.04.2019
LT17.04.2019
LV17.04.2019
NL17.04.2019
PL17.04.2019
RO17.04.2019
RS17.04.2019
SE17.04.2019
SK17.04.2019
BG17.07.2019
NO17.07.2019
GR18.07.2019
IS17.08.2019
PT17.08.2019
Former [2020/10]AL17.04.2019
AT17.04.2019
CZ17.04.2019
DK17.04.2019
FI17.04.2019
HR17.04.2019
LT17.04.2019
LV17.04.2019
NL17.04.2019
PL17.04.2019
RO17.04.2019
RS17.04.2019
SE17.04.2019
BG17.07.2019
NO17.07.2019
GR18.07.2019
IS17.08.2019
PT17.08.2019
Former [2020/09]AL17.04.2019
CZ17.04.2019
DK17.04.2019
FI17.04.2019
HR17.04.2019
LT17.04.2019
LV17.04.2019
NL17.04.2019
PL17.04.2019
RS17.04.2019
SE17.04.2019
BG17.07.2019
NO17.07.2019
GR18.07.2019
IS17.08.2019
PT17.08.2019
Former [2020/04]AL17.04.2019
FI17.04.2019
HR17.04.2019
LT17.04.2019
LV17.04.2019
NL17.04.2019
PL17.04.2019
RS17.04.2019
SE17.04.2019
BG17.07.2019
NO17.07.2019
GR18.07.2019
IS17.08.2019
PT17.08.2019
Former [2019/52]AL17.04.2019
FI17.04.2019
HR17.04.2019
LT17.04.2019
LV17.04.2019
NL17.04.2019
PL17.04.2019
RS17.04.2019
SE17.04.2019
BG17.07.2019
NO17.07.2019
GR18.07.2019
PT17.08.2019
Former [2019/51]AL17.04.2019
FI17.04.2019
HR17.04.2019
LT17.04.2019
LV17.04.2019
NL17.04.2019
RS17.04.2019
SE17.04.2019
BG17.07.2019
NO17.07.2019
GR18.07.2019
PT17.08.2019
Former [2019/50]AL17.04.2019
FI17.04.2019
HR17.04.2019
LT17.04.2019
LV17.04.2019
NL17.04.2019
RS17.04.2019
SE17.04.2019
NO17.07.2019
GR18.07.2019
PT17.08.2019
Former [2019/49]AL17.04.2019
FI17.04.2019
HR17.04.2019
LT17.04.2019
NL17.04.2019
SE17.04.2019
NO17.07.2019
PT17.08.2019
Former [2019/48]FI17.04.2019
LT17.04.2019
NL17.04.2019
SE17.04.2019
NO17.07.2019
PT17.08.2019
Former [2019/47]FI17.04.2019
LT17.04.2019
NL17.04.2019
NO17.07.2019
Former [2019/44]NL17.04.2019
Cited inInternational search[A]WO0104157  (UNIV SOUTHERN CALIFORNIA [US]) [A] 1-41 * the whole document *;
 [A]WO2004022096  (ALEXION PHARMA INC [US], et al) [A] 1-41 * the whole document *;
 [XA]WO2007094842  (GENENTECH INC [US], et al) [X] 1,19,32 * the whole document * * in particular * * abstract * * figure 11A; sequence 413 * [A] 2-18,20-31,33-41;
 [XA]WO2008154439  (IRM LLC, et al) [X] 3,19,32 * the whole document * * in particular * * abstract * * claim 4; sequence 59 * [A] 1,2,4-18,20-31,33-41;
 [XI]WO2009111450  (DYAX CORP [US], et al) [X] 1,12,13,17-24,32,35-39 * the whole document * * in particular * * abstract * * page 1, line 14 - page 12, line 21 * * figures 1-10; examples 1-16; claims 1-53 * [I] 2-11,14-16,25-31,33,34,40,41;
 [A]WO2009111508  (DYAX CORP [US], et al) [A] 1-41 * the whole document *;
 [A]WO2010048432  (DYAX CORP [US], et al) [A] 1-41 * the whole document *;
 [XA]WO2010059543  (MERCK SHARP & DOHME [US], et al) [X] 3,19,32 * the whole document * * in particular * * abstract * * page 239; sequence 250 * [A] 1,2,4-18,20-31,33-41;
 [A]WO2011092700  (YEDA RES & DEV [IL], et al) [A] 1-41 * the whole document *;
 [T]WO2012027721  (GILEAD BIOLOGICS INC [US], et al) [T] * the whole document *;
 [Y]  - HOLT L J ET AL, "Domain antibodies: proteins for therapy", TRENDS IN BIOTECHNOLOGY, ELSEVIER PUBLICATIONS, CAMBRIDGE, GB, (20031101), vol. 21, no. 11, doi:10.1016/J.TIBTECH.2003.08.007, ISSN 0167-7799, pages 484 - 490, XP004467495 [Y] 1-38 * the whole document *

DOI:   http://dx.doi.org/10.1016/j.tibtech.2003.08.007
 [Y]  - DAVIES J ET AL, "Affinity improvement of single antibody VH domains: residues in all three hypervariable regions affect antigen binding", IMMUNOTECHNOLOGY, ELSEVIER SCIENCE PUBLISHERS BV, NL, (19960901), vol. 2, no. 3, doi:10.1016/S1380-2933(96)00045-0, ISSN 1380-2933, pages 169 - 179, XP004070292 [Y] 1-38 * the whole document *

DOI:   http://dx.doi.org/10.1016/S1380-2933(96)00045-0
 [A]  - CARTER P J, "POTENT ANTIBODY THERAPEUTICS BY DESIGN", NATURE REVIEWS. IMMUNOLOGY, NATURE PUBLISHING GROUP, GB, (20060407), vol. 6, doi:10.1038/NRI1837, ISSN 1474-1733, pages 343 - 357, XP007901440 [A] 1-38 * the whole document *

DOI:   http://dx.doi.org/10.1038/nri1837
 [A]  - WARK K L ET AL, "Latest technologies for the enhancement of antibody affinity", ADVANCED DRUG DELIVERY REVIEWS, ELSEVIER BV, AMSTERDAM, NL, vol. 58, no. 5-6, doi:10.1016/J.ADDR.2006.01.025, ISSN 0169-409X, (20060807), pages 657 - 670, (20060807), XP024892147 [A] 1-38 * the whole document *

DOI:   http://dx.doi.org/10.1016/j.addr.2006.01.025
 [A]  - MARTENS ET AL, "A monoclonal antibody inhibits gelatinase B/MMP-9 by selective binding to part of the catalytic domain and not to the fibronectin or zinc binding domains", BIOCHIMICA ET BIOPHYSICA ACTA - GENERAL SUBJECTS, ELSEVIER SCIENCE PUBLISHERS, NL, (20061229), vol. 1770, no. 2, doi:10.1016/J.BBAGEN.2006.10.012, ISSN 0304-4165, pages 178 - 186, XP005818408 [A] 1-41 * the whole document *

DOI:   http://dx.doi.org/10.1016/j.bbagen.2006.10.012
 [A]  - JIALIANG HU ET AL, "Inhibitors of gelatinase B/matrix metalloproteinase-9 activity comparison of a peptidomimetic and polyhistidine with single-chain derivatives of a neutralizing monoclonal antibody.", BIOCHEMICAL PHARMACOLOGY, (20040301), vol. 67, no. 5, ISSN 0006-2952, pages 1001 - 1009, XP055042352 [A] 1-41 * the whole document *

DOI:   http://dx.doi.org/10.1016/j.bcp.2003.10.030
by applicantUS4816567
 EP0404097
 WO9311161
 US5391377
 US5545807
 US5545806
 US5569825
 US5625126
 US5633425
 US5661016
    - Methods in Enzymology, ACADEMIC PRESS
    - HU ET AL., NATURE REVIEWS: DRUG DISCOVERY, (2007), vol. 6, pages 480 - 498
    - ALTSCHUL ET AL., J. MOL. BIOL., (1990), vol. 215, pages 403 - 410
    - ALTSCHUL ET AL., NUCLEIC ACIDS RES., (1977), vol. 25, pages 3389 - 3402
    - HIGGINS D. ET AL., NUCLEIC ACIDS RES, (1994), vol. 22, pages 4673 - 4680
    - ZAPATA ET AL., PROTEIN ENG., (1995), vol. 8, no. 10, pages 1057 - 1062
    - PLUCKTHUN, The Pharmacology of Monoclonal Antibodies, SPRINGER-VERLAG, (1994), vol. 113, pages 269 - 315
    - HOLLINGER ET AL., PROC. NATL. ACAD. SCI. USA, (1993), vol. 90, pages 6444 - 6448
    - KABAT ET AL., J. BIOL. CHEM., (1977), vol. 252, pages 6609 - 6616
    - CHOTHIA ET AL., J. MOL. BIOL., (1987), vol. 196, pages 901 - 917
    - MACCALLUM ET AL., J. MOL. BIOL., (1996), vol. 262, pages 732 - 745
    - JONES ET AL., NATURE, (1986), vol. 321, pages 522 - 525
    - RIECHMANN ET AL., NATURE, (1988), vol. 332, pages 323 - 329
    - PRESTA, CURR. OP. STRUCT. BIOL., (1992), vol. 2, pages 593 - 596
    - VERHOEYEN ET AL., SCIENCE, (1988), vol. 239, pages 1534 - 1536
    - HOOGENBOOM ET AL., J. MOL. BIOL, (1991), vol. 227, page 381
    - MARKS ET AL., J. MOL. BIOL., (1991), vol. 222, page 581
    - COLE ET AL., Monoclonal Antibodies and Cancer Therapy, ALAN R. LISS, (1985), page 77
    - BOEMER ET AL., J. IMMUNOL., (1991), vol. 147, pages 86 - 95
    - MARKS ET AL., BIO/I'ECHNOLOGY, (1992), vol. 10, pages 779 - 783
    - LONBERG ET AL., NATURE, (1994), vol. 368, pages 856 - 859
    - MORRISON, NATURE, (1994), vol. 368, pages 812 - 813
    - FISHWALD ET AL., NATURE BIOTECHNOLOGY, (1996), vol. 14, pages 845 - 851
    - NEUBERGER, NATURE BIOTECHNOLOGY, (1996), vol. 14, page 826
    - LONBERG ET AL., INTERN. REV. IMMUNOL., (1995), vol. 13, pages 65 - 93
    - ANGAL ET AL., MOLEC. IMMUNOL., (1993), vol. 30, pages 105 - 108
    - BAI, J. NEUROIMMUNOL., (1997), vol. 80, pages 65 - 75
    - WARREN, J. NEUROL. SCI., (1997), vol. 152, pages 31 - 38
    - TONEGAWA, J. EXP. MED., (1997), vol. 186, pages 505 - 515
    - FIX, PHARM RES., (1996), vol. 13, pages 1760 - 1764
    - SAMANEN, J. PHARM. PHARMACOL., (1996), vol. 48, pages 119 - 135
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.